Sharing is caring!

Data analytics of bio-processing allows better control over processes which results in an improved product.   

Talks such as switching to using single-use technology and the increased digitalization of manufacturing to improve efficiency in manufacturing have always been present within the industry.  

In an interview with Mr. Peter Levison (Executive Director of Business Development in Pall Biotech) with BioPharma-Reporter, he mentioned the recent major changes within the industry, advantages of continuous bio-processing, how to implement it and the difference between data generation in batches and continuously.

Major changes that Mr. Levison mentioned are the intensification of processes, the higher titers and the greater potency of the drugs that reduced the amount required that companies need per year are highly prevalent in the industry today.  

Mr. Levison also mentioned the different technologies that Pall Biotech offers, Virtual Reality and Digital Twins that are already being used in the change of the processes.

Virtual reality is used in making a Digital twin that enables the evaluation of different production scenarios and create risk mitigation strategies.

This is to ensure that optimization is achieved to ensure maximum efficacy of equipment and to optimize the facility’s design layout that ensures that a suitable environment is used.

Analytics and Control will also soon be added to their company’s repertoire.  

A report from Deloitte listed out the advantages of using technology in processes, smaller footprints, and lower scale-up requirements.

The report highlighted that despite the advantages of technology adoption, risks in quality control is also present.

Mr. Levison disagreed and suggests that the amount of data generated and used through bio-processing can benefit the product’s final quality traits.   

Mr. Levison also suggested in the interview that companies should consider in taking hybrid approaches instead of traditional methods when adopting continuous bio-processing in their company.

The hybrid approaches allow the selection and the mixing of the most effective techniques for each stage of the process.

With a wide range of tools available today, implementing hybrid approaches are easier.   

And he also explained the difference between data generation by batches and continuously.

Through batches, the amount of data generated is limited because of its defined timeline of data collection.

Whereas the continuous generation of data do not have a defined timeline that enables access to real-time statistics, helping improve efficiency in the processes and quality improvements.   

Mr. Levison said in his closing remarks that Pall Biotech is a data-driven company that fully offers continuous solutions catered to each company.

They are confident that their technology will help in companies’ bio-processes as they endlessly ensure that constant improvements are made.

(Source: BioPharma Reporter, 2019)